Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (81-90 of 302) with videos related to

Pageof 31
Sort By:
Cancer Chemotherapy and Pharmacology|January 19, 2016
Pharmacokinetic interaction between pazopanib and cisplatin regimenDiane-Charlotte Imbs, Véronique Diéras, Thomas Bachelot, et al.
Breast Cancer Research : BCR|November 11, 2023
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancerMario Campone, François-Clément Bidard, Patrick Neven, et al.
Cytokine|July 31, 2009
Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancerMichel Chérel, Loïc Campion, Stéphane Bézieau, et al.
Clinical Breast Cancer|January 19, 2019
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II StudyKimberly L Blackwell, Khalil Zaman, Shukui Qin, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Cancer Causes & Control : CCC|December 21, 2016
Short-term and long-term survival of interval breast cancers taking into account prognostic featuresSolenne Delacour-Billon, Anne Laure Mathieu-Wacquant, Mario Campone, et al.
Molecular & Cellular Proteomics : MCP|July 26, 2015
Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue SamplesMario Campone, Isabelle Valo, Pascal Jézéquel, et al.
Oncotarget|October 21, 2015
Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosisAlexandra Vétillard, Barbara Jonchère, Marie Moreau, et al.
Cancers|December 16, 2020
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer PatientsCamille Moreau-Bachelard, Loïc Campion, Marie Robert, et al.
Therapeutic Advances in Medical Oncology|May 23, 2017
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapyPaule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, et al.
Pageof 31

Showing results (81-90 of 302) with videos related to

Sort By:
Pageof 31
Cancer Chemotherapy and Pharmacology|January 19, 2016
Pharmacokinetic interaction between pazopanib and cisplatin regimenDiane-Charlotte Imbs, Véronique Diéras, Thomas Bachelot, et al.
Breast Cancer Research : BCR|November 11, 2023
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancerMario Campone, François-Clément Bidard, Patrick Neven, et al.
Cytokine|July 31, 2009
Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancerMichel Chérel, Loïc Campion, Stéphane Bézieau, et al.
Clinical Breast Cancer|January 19, 2019
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II StudyKimberly L Blackwell, Khalil Zaman, Shukui Qin, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Cancer Causes & Control : CCC|December 21, 2016
Short-term and long-term survival of interval breast cancers taking into account prognostic featuresSolenne Delacour-Billon, Anne Laure Mathieu-Wacquant, Mario Campone, et al.
Molecular & Cellular Proteomics : MCP|July 26, 2015
Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue SamplesMario Campone, Isabelle Valo, Pascal Jézéquel, et al.
Oncotarget|October 21, 2015
Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosisAlexandra Vétillard, Barbara Jonchère, Marie Moreau, et al.
Cancers|December 16, 2020
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer PatientsCamille Moreau-Bachelard, Loïc Campion, Marie Robert, et al.
Therapeutic Advances in Medical Oncology|May 23, 2017
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapyPaule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, et al.
Pageof 31